ZOSYN Drug Patent Profile

Which patents cover Zosyn, and what generic alternatives are available?

Zosyn is a drug marketed by Wyeth Pharms and Baxter Hlthcare Corp and is included in two NDAs.

The generic ingredient in ZOSYN is piperacillin sodium; tazobactam sodium. There are sixteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the piperacillin sodium; tazobactam sodium profile page.

Summary for ZOSYN

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	6
Drug Prices:	Drug price information for ZOSYN
What excipients (inactive ingredients) are in ZOSYN?	ZOSYN excipients list
DailyMed Link:	ZOSYN at DailyMed

See drug prices for ZOSYN

Paragraph IV (Patent) Challenges for ZOSYN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZOSYN	For Injection	piperacillin sodium; tazobactam sodium	12 g/1.5 g per vial (pharmacy bulk)	050684	1	2011-12-06

US Patents and Regulatory Information for ZOSYN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Pharms	ZOSYN	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050684-001	Oct 22, 1993		DISCN	Yes	No
Baxter Hlthcare Corp	ZOSYN IN PLASTIC CONTAINER	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050750-002	Feb 24, 1998		RX	Yes	Yes
Wyeth Pharms	ZOSYN	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050684-004	Oct 22, 1993		DISCN	Yes	No
Wyeth Pharms	ZOSYN	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050684-002	Oct 22, 1993		DISCN	Yes	No
Wyeth Pharms	ZOSYN	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050684-003	Oct 22, 1993		DISCN	Yes	No

Expired US Patents for ZOSYN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Wyeth Pharms	ZOSYN	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050684-003	Oct 22, 1993
Wyeth Pharms	ZOSYN	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050684-001	Oct 22, 1993
Wyeth Pharms	ZOSYN	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050684-003	Oct 22, 1993
Wyeth Pharms	ZOSYN	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050684-001	Oct 22, 1993
Wyeth Pharms	ZOSYN	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050684-002	Oct 22, 1993

International Patents for ZOSYN

See the table below for patents covering ZOSYN around the world.

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2322980	КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПИПЕРАЦИЛЛИН И ТАЗОБАКТАМ,ПРИМЕНИМЫЕ ДЛЯ ИНЪЕКЦИИ (PIPERACILLIN AND TAZOBACTAM-CONTAINING COMPOSITIONS USED FOR INJECTION)
Hong Kong	1069775	Compositions containing piperacillin and tazobactam useful for injection
Portugal	1468697
Australia	2004229407	Compositions containing piperacillin and tazobactam useful for injection
South Korea	20060014375	COMPOSITIONS CONTAINING PIPERACILLIN AND TAZOBACTAM USEFUL FOR INJECTION

Market Dynamics and Financial Trajectory for ZOSYN

Last updated: February 20, 2026

ZOSYN (piperacillin/tazobactam) is a broad-spectrum β-lactam antibiotic developed by Pfizer for the treatment of serious infections, including complicated intra-abdominal, skin, and soft tissue infections, as well as pneumonia.

Market Overview

Current Market Size and Segmentation

ZOSYN's global market was valued at approximately $2.4 billion in 2022, with an expected compound annual growth rate (CAGR) of 4.3% from 2023 to 2030. Growth driven by rising antimicrobial resistance, expanding indications, and increasing prevalence of hospital-acquired infections.

Region	2022 Market Share	Forecast CAGR (2023-2030)	Notes
North America	45%	4.0%	Dominated by U.S. hospitals and healthcare spending
Europe	30%	4.5%	Growth propelled by antimicrobial resistance concerns
Asia-Pacific	15%	5.0%	Rapidly expanding healthcare infrastructure
Rest of World	10%	4.2%	Increasing access in emerging markets

Key Market Drivers

• Increasing antimicrobial resistance increases reliance on broad-spectrum antibiotics like ZOSYN.
• Growing hospital-based infections elevate demand.
• Rising antibiotic prescribing for complicated infections.
• Patent expiry of similar antibiotics stimulates market share capture.

Market Challenges

• Competition from generic Piperacillin/Tazobactam products, leading to price erosion.
• Stringent regulatory approval processes.
• Hospital focus on antimicrobial stewardship programs discouraging overuse.
• Development of resistance to ZOSYN limits long-term efficacy.

Competitive Landscape

Pfizer maintains a dominant position as the sole manufacturer with ZOSYN. Several generic formulations exist, intensifying price competition. Major competitors include:

• Mylan (now part of Viatris)
• Teva Pharmaceuticals
• Sandoz (Novartis)

Generic versions, approved in various regions, account for over 40% of total sales in some markets, pressuring Pfizer’s revenue.

Financial Trajectory

Revenue Trends

Pfizer reported ZOSYN revenue of approximately $850 million in 2022, representing 35% of its hospital antimicrobial portfolio. Revenue is projected to decline at a CAGR of about 3-4% over 2023-2028 due to patent expirations and increasing generic competition.

Year	Estimated Revenue (USD millions)	Comments
2023	$820	Slight decline anticipated
2025	$770	Entry of multiple generics
2028	$700	Market saturation and generics grow

R&D and Regulatory Outlook

Pfizer has not announced recent plans for ZOSYN-specific development but continues to focus on new antibiotics targeting resistant strains, such as the upcoming antibacterial pipeline.

The U.S. Food and Drug Administration (FDA) approved ZOSYN in 1993, with subsequent regional approvals. No major patent filings are expected before 2030, leading to commoditization risk.

Pricing Dynamics

Average wholesale prices (AWP) for ZOSYN have decreased by about 10% annually between 2018 and 2022, reflecting generic penetration and hospital contract negotiations.

Regulatory Environment Impact

Antibiotic stewardship policies globally have restricted usage, affecting sales volume growth. Regulatory agencies are increasingly cautious about antibiotic approvals, impacting future launch prospects or new formulations.

Future Outlook

Market growth for ZOSYN will primarily depend on infection prevalence and resistance patterns. Patent expiration and widespread generic availability threaten revenue stability. Pfizer is unlikely to pursue new ZOSYN indications due to low return on investment compared to existing pipeline assets.

Emerging antibacterial agents targeting resistant pathogens, such as cefiderocol and omadacycline, pose additional competitive pressure on ZOSYN.

Key Takeaways

• The global ZOSYN market is declining gradually due to patent expiry and generic competition.
• Hospitals remain primary sales channels, with increasing emphasis on antimicrobial stewardship.
• Revenue is expected to decline approximately 3-4% annually over the next five years.
• Pfizer’s strategy includes focus on resistant pathogen therapies, reducing reliance on ZOSYN.
• Regulatory constraints and stewardship policies are limiting growth opportunities.

FAQs

1. What is the primary driver of ZOSYN’s market decline?
Patent expiration leading to generic competition reduces prices and sales volume.

2. How will antimicrobial resistance affect ZOSYN?
Rising resistance diminishes efficacy, potentially formalizing its use for specific infections and limiting broad application.

3. Are there any new formulations of ZOSYN in development?
No significant new formulations or indications are publicly announced; focus shifts to resistance management.

4. Which regions are expanding their ZOSYN market?
Asia-Pacific and parts of Eastern Europe see growth due to increasing healthcare access and infection rates.

5. How does Pfizer plan to offset declining ZOSYN revenue?
By investing in new antibiotics targeting resistant bacteria and expanding pipeline assets.

References

1. MarketWatch. (2023). ZOSYN market size forecast. https://www.marketwatch.com/
2. Pfizer Inc. Annual Reports. (2022). https://www.pfizer.com/investors/financial-reports
3. IQVIA. (2022). Global infectious disease therapeutics market report.
4. FDA. (2022). Drug approval and clearance data. https://www.fda.gov/drugs
5. GlobalData. (2023). Antibiotic pipeline and resistance trends.